# MoonLake Immunotherapeutics Class A (MLTX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $15.01, market value $1.3 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). MoonLake Immunotherapeutics Class A reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.9×**. The shares trade at 2.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -17.6%** (5-yr avg -11.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -74.7%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -86.8%**. Earnings per share fell 86.8%.

## Financial health
- **Debt to equity: 0.24**. Debt is 0.24 times equity: a conservative balance sheet.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. MoonLake Immunotherapeutics Class A does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (13 analysts). 13 analysts cover MoonLake Immunotherapeutics Class A; the consensus is buy, with an average price target of $28.54 (+90% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -74.9%** (YTD 13.9%, 3-mo -16.1%). The shares are down 74.9% over twelve months including dividends.
- **From 52-week high: -76.1%** (152.3% above the low). Trading 76% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 34**. An RSI of 34 is neutral.
- **Beta (1 yr): 1.14** (volatility 118%). Beta of 1.14 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MLTX · Page: https://foliofundamentals.com/stocks/mltx

Not investment advice.